Exploring the Efficacy of Pembrolizumab in Combination with Carboplatin and Weekly Paclitaxel for Frail Patients with Advanced Non-Small-Cell Lung Cancer: A Key Investigative Study

Exploring the Efficacy of Pembrolizumab in Combination with Carboplatin and Weekly Paclitaxel for Frail Patients with Advanced Non-Small-Cell Lung Cancer: A Key Investigative Study

Introduction: Immune checkpoint blockers have revolutionized the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Pembrolizumab, an anti-PD-1 monoclonal antibody, is a standard therapy either alone or in combination with chemotherapy (chemo-IO). The current study explores the eff...

Full description

Bibliographic Details
Main Authors: Quentin Dominique Thomas, Mohamed Chaabouni, Anas Al herk, Cesar Lefevbre, Sarah Cavaillon, Léa Sinoquet, Stéphane Pouderoux, Marie Viala, Lise Roca, Xavier Quantin
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
non-small-cell lung cancer
immunotherapy
geriatric oncology
weekly chemotherapy
prognosis
Online Access:https://www.mdpi.com/2072-6694/16/5/992

Internet

https://www.mdpi.com/2072-6694/16/5/992

Similar Items